GT Biopharma

GT Biopharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GT Biopharma (GTBP) as of Oct 22, 2026 is -12.42 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -14.36 M USD — a change of -13.52% (higher).

EBITDA

-12.42 MUSD

YoY

-13.52%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GT Biopharma is 2025 -12.42 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GT Biopharma was 2024 -14.36 M USD. It decreases by -13.52% higher compared to the previous year.

The GT Biopharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-250.07 M USD
Jan 1, 2019
-36.52 M USD
Jan 1, 2020
-6.76 M USD
Jan 1, 2021
-57.52 M USD
Jan 1, 2022
-21.26 M USD
Jan 1, 2023
-13.58 M USD
Jan 1, 2024
-14.36 M USD
Jan 1, 2025
-12.42 M USD
The GT Biopharma EBITDA history
YEAREBITDAYoY
-12.42 MUSD-13.52%
-14.36 MUSD+5.80%
-13.58 MUSD-36.13%
-21.26 MUSD-63.04%
-57.52 MUSD+750.31%
-6.76 MUSD-81.48%
-36.52 MUSD-85.40%
-250.07 MUSD+84.46%
-135.57 MUSD+1,346.23%
-9.37 MUSD+5.01%
-8.93 MUSD+272.58%
-2.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GT Biopharma is -12.42 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GT Biopharma changed from -14.36 M USD to -12.42 M USD, representing a -13.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GT Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GT Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GT Biopharma